Alumis Inc.

Based on the Company s current operating plan, Alumis continues to anticipate that its existing cash, cash equivalents and marketable securities as of June 30, 2025 is expected to support advancement of its pipeline through multiple planned key clinical data readouts and to fund operating expenses and capital expenditure requirements into 2027.

SEC original ↗Alumis Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2025

The Company s management continuously monitors and, where necessary, may reduce its operating expenses in response to its clinical development progress and its ability and need to raise additional capital through a combination of public and private equity, debt financings, strategic alliances and licensing arrangements.

SEC original ↗Alumis Inc. — 10-Q Quarterly report10-QAug 13, 2026

Treasury obligations, commercial paper, corporate debt obligations, supranational debt obligations, and government development bank obligations, which can be subject to certain credit risks.

SEC original ↗Alumis Inc. — 10-Q Quarterly report10-QAug 13, 2026

Treasury obligations, corporate debt obligations, commercial paper, supranational debt obligations and government development bank obligations.

SEC original ↗Alumis Inc. — 10-Q Quarterly report10-QAug 13, 2026

Treasury obligations 200,366 101,091 301,457 Corporate debt obligations 86,859 86,859 Commercial paper 48,274 48,274 Supranational debt obligations 1,997 1,997 Total assets $ 259,075 $ 238,221 $ $ 497,296 December 31, 2025 Level 1 Level 2 Level 3 Total Assets: Cash equivalents Money market funds $ 81,729 $ $ $ 81,729 U.

SEC original ↗Alumis Inc. — 10-Q Quarterly report10-QAug 13, 2026

We continue to move forward on all fronts with momentum and a clear focus on advancing a differentiated pipeline of immune-mediated treatments.

SEC original ↗Alumis Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2025

Pipeline Updates A -005, potentially first-in-class fully CNS-penetrant TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases o A-005 continues to advance towards Phase 2 clinical trial initiation with CMC and pharmacology activities on track, and ongoing preclinical and genetic research efforts to support potential expansion into additional neurodegenerative indications.

SEC original ↗Alumis Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2025

All statements, other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements.

SEC original ↗Alumis Inc. — 10-Q Quarterly report10-QAug 13, 2026

(the Company ) is a clinical stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders.

SEC original ↗Alumis Inc. — 10-Q Quarterly report10-QAug 13, 2026

The Company s management continuously monitors and, where necessary, may reduce its operating expenses in response to its clinical development progress and its ability and need to raise additional capital through a combination of public and private equity, debt financings, strategic alliances and licensing arrangements.

SEC original ↗Alumis Inc. — 10-Q Quarterly report10-QAug 13, 2026

Any forward-looking statements in this press release are based on Alumis current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements.

SEC original ↗Alumis Inc. — Earnings release (8-K exhibit)EX-99Aug 13, 2025

Legal Proceedings 55 Item 1A.

SEC original ↗Alumis Inc. — 10-Q Quarterly report10-QAug 13, 2026

These forward-looking statements involve risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.

SEC original ↗Alumis Inc. — 10-Q Quarterly report10-QAug 13, 2026

In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.

SEC original ↗Alumis Inc. — 10-Q Quarterly report10-QAug 13, 2026

Further, the Company s business and results of operations may be affected by worldwide economic conditions, which may continue to be impacted by global macroeconomic challenges and uncertainty in the markets, including international trade policies and tariffs, severely diminished liquidity and credit availability, rising inflation and monetary supply shifts, rising interest rates, labor shortages, declines in consumer confidence, declines in economic growth, increases in unemployment rates, recession risks and uncertainty about economic and geopolitical stability.

SEC original ↗Alumis Inc. — 10-Q Quarterly report10-QAug 13, 2026

The United States and other countries have imposed and may continue to impose new trade restrictions and export regulations, have levied tariffs and taxes on certain goods, including tariffs targeting pharmaceutical products and related inputs, and could continue to significantly increase tariffs on a broad array of goods.

SEC original ↗Alumis Inc. — 10-Q Quarterly report10-QAug 13, 2026